These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 12021277)

  • 1. Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation.
    Hanasaki K; Yamada K; Yamamoto S; Ishimoto Y; Saiga A; Ono T; Ikeda M; Notoya M; Kamitani S; Arita H
    J Biol Chem; 2002 Aug; 277(32):29116-24. PubMed ID: 12021277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Group V secretory phospholipase A2-modified low density lipoprotein promotes foam cell formation by a SR-A- and CD36-independent process that involves cellular proteoglycans.
    Boyanovsky BB; van der Westhuyzen DR; Webb NR
    J Biol Chem; 2005 Sep; 280(38):32746-52. PubMed ID: 16040605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation.
    Wooton-Kee CR; Boyanovsky BB; Nasser MS; de Villiers WJ; Webb NR
    Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):762-7. PubMed ID: 14962950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Group V and X secretory phospholipase A(2)s-induced modification of high-density lipoprotein linked to the reduction of its antiatherogenic functions.
    Ishimoto Y; Yamada K; Yamamoto S; Ono T; Notoya M; Hanasaki K
    Biochim Biophys Acta; 2003 Oct; 1642(3):129-38. PubMed ID: 14572896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hawthorn leaf flavonoids alleviate the deterioration of atherosclerosis by inhibiting SCAP-SREBP2-LDLR pathway through sPLA2-ⅡA signaling in macrophages in mice.
    Bai X; Wang S; Shu L; Cao Q; Hu H; Zhu Y; Chen C
    J Ethnopharmacol; 2024 Jun; 327():118006. PubMed ID: 38442806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mouse group X secretory phospholipase A2 induces a potent release of arachidonic acid from spleen cells and acts as a ligand for the phospholipase A2 receptor.
    Morioka Y; Saiga A; Yokota Y; Suzuki N; Ikeda M; Ono T; Nakano K; Fujii N; Ishizaki J; Arita H; Hanasaki K
    Arch Biochem Biophys; 2000 Sep; 381(1):31-42. PubMed ID: 11019817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage-specific overexpression of group IIa sPLA2 increases atherosclerosis and enhances collagen deposition.
    Ghesquiere SA; Gijbels MJ; Anthonsen M; van Gorp PJ; van der Made I; Johansen B; Hofker MH; de Winther MP
    J Lipid Res; 2005 Feb; 46(2):201-10. PubMed ID: 15576846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A modification of apolipoprotein B accounts for most of the induction of macrophage growth by oxidized low density lipoprotein.
    Martens JS; Lougheed M; Gómez-Muñoz A; Steinbrecher UP
    J Biol Chem; 1999 Apr; 274(16):10903-10. PubMed ID: 10196168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences between group X and group V secretory phospholipase A(2) in lipolytic modification of lipoproteins.
    Kamitani S; Yamada K; Yamamoto S; Ishimoto Y; Ono T; Saiga A; Hanasaki K
    Cell Mol Biol Lett; 2012 Sep; 17(3):459-78. PubMed ID: 22706677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis.
    Sato H; Kato R; Isogai Y; Saka G; Ohtsuki M; Taketomi Y; Yamamoto K; Tsutsumi K; Yamada J; Masuda S; Ishikawa Y; Ishii T; Kobayashi T; Ikeda K; Taguchi R; Hatakeyama S; Hara S; Kudo I; Itabe H; Murakami M
    J Biol Chem; 2008 Nov; 283(48):33483-97. PubMed ID: 18801741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secretory phospholipase A2 and lipoprotein lipase enhance 15-lipoxygenase-induced enzymic and nonenzymic lipid peroxidation in low-density lipoproteins.
    Neuzil J; Upston JM; Witting PK; Scott KF; Stocker R
    Biochemistry; 1998 Jun; 37(25):9203-10. PubMed ID: 9636068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100.
    Flood C; Gustafsson M; Pitas RE; Arnaboldi L; Walzem RL; Borén J
    Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):564-70. PubMed ID: 14726411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress.
    Tietge UJ; Pratico D; Ding T; Funk CD; Hildebrand RB; Van Berkel T; Van Eck M
    J Lipid Res; 2005 Aug; 46(8):1604-14. PubMed ID: 15897607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New phospholipase A(2) isozymes with a potential role in atherosclerosis.
    Murakami M; Kudo I
    Curr Opin Lipidol; 2003 Oct; 14(5):431-6. PubMed ID: 14501581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Covalent binding of oxidized cholesteryl esters to protein: implications for oxidative modification of low density lipoprotein and atherosclerosis.
    Kawai Y; Saito A; Shibata N; Kobayashi M; Yamada S; Osawa T; Uchida K
    J Biol Chem; 2003 Jun; 278(23):21040-9. PubMed ID: 12663661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzymatic modification of low density lipoprotein by purified lipoxygenase plus phospholipase A2 mimics cell-mediated oxidative modification.
    Sparrow CP; Parthasarathy S; Steinberg D
    J Lipid Res; 1988 Jun; 29(6):745-53. PubMed ID: 3139813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modification of low density lipoprotein with 4-hydroxynonenal induces uptake by macrophages.
    Hoff HF; O'Neil J; Chisolm GM; Cole TB; Quehenberger O; Esterbauer H; Jürgens G
    Arteriosclerosis; 1989; 9(4):538-49. PubMed ID: 2751482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Participation of the arachidonic acid cascade pathway in macrophage binding/uptake of oxidized low density lipoprotein.
    Beppu M; Watanabe M; Sunohara M; Ohishi K; Mishima E; Kawachi H; Fujii M; Kikugawa K
    Biol Pharm Bull; 2002 Jun; 25(6):710-7. PubMed ID: 12081134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The capacity of group V sPLA2 to increase atherogenicity of ApoE-/- and LDLR-/- mouse LDL in vitro predicts its atherogenic role in vivo.
    Boyanovsky B; Zack M; Forrest K; Webb NR
    Arterioscler Thromb Vasc Biol; 2009 Apr; 29(4):532-8. PubMed ID: 19164803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The catalytically active secretory phospholipase A2 type IIA is involved in restenosis development after PTCA in human coronary arteries and generation of atherogenic LDL.
    Korotaeva AA; Samoilova EV; Kaminny AI; Pirkova AA; Resink TJ; Erne P; Prokazova NV; Tkachuk VA; Chazov EI
    Mol Cell Biochem; 2005 Feb; 270(1-2):107-13. PubMed ID: 15792359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.